Assessment of vaccine candidates for persons aged 50 and older: a review

[1]  V. C. Edwards.  Benefits , 1993, Encyclopedia of Evolutionary Psychological Science.

[2]  H. D. de Melker,et al.  Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands. , 2012, Vaccine.

[3]  M. Leinonen,et al.  Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects , 2012, Scandinavian journal of infectious diseases.

[4]  K. Schmader,et al.  Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. , 2012, Vaccine.

[5]  L. Annemans,et al.  A critical literature review of health economic evaluations in pertussis booster vaccination , 2012, Expert review of pharmacoeconomics & outcomes research.

[6]  B. Vaes,et al.  Associations Between Cytomegalovirus Infection and Functional Impairment and Frailty in the BELFRAIL Cohort , 2011, Journal of the American Geriatrics Society.

[7]  A. Hermans.  Old man's friend , 2011 .

[8]  S. Thomas,et al.  Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥50 years , 2011, Human vaccines.

[9]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[10]  P. van Damme,et al.  Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. , 2011, Vaccine.

[11]  M. P. van der Linden,et al.  Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe , 2011, Expert review of vaccines.

[12]  S. Geraci,et al.  Adult immunizations: update on recommendations. , 2011, The American journal of medicine.

[13]  E. Emini,et al.  A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. , 2011, Vaccine.

[14]  J. Michel,et al.  Immunosenescence: Implications for vaccination programmes in adults. , 2011, Maturitas.

[15]  FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. , 2011, MMWR. Morbidity and mortality weekly report.

[16]  W. Schaffner,et al.  Keeping our Adult Patients Healthy and Active: The Role of Vaccines across the Lifespan , 2010, The Physician and sportsmedicine.

[17]  F. Mooi,et al.  Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis , 2010, PloS one.

[18]  K. Schmader,et al.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study , 2010, Canadian Medical Association Journal.

[19]  K. Schmader,et al.  Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older Adults , 2010, Journal of the American Geriatrics Society.

[20]  H. D. de Melker,et al.  Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands , 2010, BMC health services research.

[21]  M. Postma,et al.  Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. , 2010, Clinical therapeutics.

[22]  M. Oxman.  Zoster vaccine: current status and future prospects. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Hong.  Update on pertussis and pertussis immunization , 2010, Korean journal of pediatrics.

[24]  L. Mollema,et al.  PIENTER 2-project: second research project on the protection against infectious diseases offered by the national immunization programme in the Netherlands , 2010 .

[25]  L. Friedland,et al.  Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults , 2009, Human vaccines.

[26]  J. Haagsma,et al.  Disease burden and costs of selected foodborne pathogens in the Netherlands, 2006 , 2009 .

[27]  L. Mascola,et al.  The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella Vaccination , 2009, The Pediatric infectious disease journal.

[28]  F. Mooi,et al.  Bordetella pertussis Strains with Increased Toxin Production Associated with Pertussis Resurgence , 2009, Emerging infectious diseases.

[29]  R. Veenhoven,et al.  Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  S. Maggi,et al.  Coalition of advocates to vaccinate of Western European citizens aged 60 years and older , 2009, Aging clinical and experimental research.

[31]  R. Veenhoven,et al.  Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. , 2009, Vaccine.

[32]  F. Mooi,et al.  Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. , 2009, Vaccine.

[33]  R. Verheij,et al.  Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia , 2009, Epidemiology and Infection.

[34]  R. Harpaz,et al.  Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. , 2009, Vaccine.

[35]  L. Hrivniaková,et al.  Hepatitis A outbreak in a Roma village in eastern Slovakia, August-November 2008. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[36]  H. Vennema,et al.  Community-wide outbreak of hepatitis A in Latvia in 2008 - an update. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[37]  Č. Beneš,et al.  Increase in hepatitis A cases in the Czech Republic in 2008 - an update. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[38]  A. Sauerbrei,et al.  Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes. , 2009, Virology.

[39]  I. Lucenko,et al.  Community-wide outbreak of hepatitis A in Latvia, in 2008. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[40]  D. Grobbee,et al.  Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. , 2008, The Netherlands journal of medicine.

[41]  Ismael R Ortega-Sanchez,et al.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[42]  W. Schaffner.  Update on vaccine-preventable diseases: are adults in your community adequately protected? , 2008, Journal of Family Practice.

[43]  K. Schmader,et al.  The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. , 2008, The Journal of infectious diseases.

[44]  J. Holden,et al.  Vaccines for preventing pneumococcal infection in adults. , 2008, The Cochrane database of systematic reviews.

[45]  A. Hoes,et al.  Influenza- and respiratory syncytial virus-associated mortality and hospitalisations , 2007, European Respiratory Journal.

[46]  M. Levin,et al.  Prevention of herpes zoster and its painful and debilitating complications. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[47]  K. Schmader.  Herpes zoster and postherpetic neuralgia in older adults. , 2007, Clinics in geriatric medicine.

[48]  T. Lieu,et al.  Cost effectiveness of pertussis vaccination in adults. , 2007, American journal of preventive medicine.

[49]  G. Castellani,et al.  Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans , 2007, Mechanisms of Ageing and Development.

[50]  Mirjam Kretzschmar,et al.  The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. , 2006, The Journal of infection.

[51]  D. Bernstein,et al.  Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  T. Kimman,et al.  Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. , 2006, Vaccine.

[53]  H. D. de Melker,et al.  The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. , 2006, Vaccine.

[54]  B. Genton,et al.  Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. , 2006, Journal of travel medicine.

[55]  Susan Partridge,et al.  Efficacy of an acellular pertussis vaccine among adolescents and adults. , 2005, The New England journal of medicine.

[56]  P. Peduzzi,et al.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.

[57]  R. Zimmerman.  If pneumonia is the "old man's friend", should it be prevented by vaccination? An ethical analysis. , 2005, Vaccine.

[58]  Aaron M Wendelboe,et al.  Duration of Immunity Against Pertussis After Natural Infection or Vaccination , 2005, The Pediatric infectious disease journal.

[59]  T. Jefferson,et al.  Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[60]  R. Dworkin,et al.  Acute pain in herpes zoster and its impact on health-related quality of life. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  M. Costa-Mattioli,et al.  Genetic variability of hepatitis A virus. , 2003, The Journal of general virology.

[62]  P. van Damme,et al.  Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use , 2002, Expert review of vaccines.

[63]  S. Halperin,et al.  Morbidity of pertussis in adolescents and adults. , 2000, The Journal of infectious diseases.

[64]  T. Yoshikawa,et al.  Epidemiology and unique aspects of aging and infectious diseases. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  J. Schellekens,et al.  An Epidemic of Pertussis Among Elderly People in a Religious Institution in The Netherlands , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[66]  H. D. de Melker,et al.  Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. , 1998, Epidemiology and infection.

[67]  Z. Bittar.  Hepatitis A vaccines. , 1996, Le Journal medical libanais. The Lebanese medical journal.

[68]  M. Thobaben,et al.  Prevention and Control of Influenza , 2003, MMWR. Morbidity and mortality weekly report.

[69]  D. Wilton,et al.  [Hepatitis A]. , 1980, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.